160 related articles for article (PubMed ID: 37951931)
21. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
Snellman A; Ekblad LL; Tuisku J; Koivumäki M; Ashton NJ; Lantero-Rodriguez J; Karikari TK; Helin S; Bucci M; Löyttyniemi E; Parkkola R; Karrasch M; Schöll M; Zetterberg H; Blennow K; Rinne JO
Alzheimers Res Ther; 2023 Apr; 15(1):71. PubMed ID: 37016464
[TBL] [Abstract][Full Text] [Related]
22. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.
Snellman A; Ekblad LL; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Pietilä E; Koivumäki M; Helin S; Karrasch M; Zetterberg H; Blennow K; Rinne JO
Neurobiol Dis; 2023 Jul; 183():106175. PubMed ID: 37268240
[TBL] [Abstract][Full Text] [Related]
23. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
24. Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
Planche V; Bouteloup V; Pellegrin I; Mangin JF; Dubois B; Ousset PJ; Pasquier F; Blanc F; Paquet C; Hanon O; Bennys K; Ceccaldi M; Annweiler C; Krolak-Salmon P; Godefroy O; Wallon D; Sauvee M; Boutoleau-Bretonnière C; Bourdel-Marchasson I; Jalenques I; Chene G; Dufouil C;
Neurology; 2023 Jan; 100(5):e473-e484. PubMed ID: 36261295
[TBL] [Abstract][Full Text] [Related]
25. Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study.
Montoliu-Gaya L; Alcolea D; Ashton NJ; Pegueroles J; Levin J; Bosch B; Lantero-Rodriguez J; Carmona-Iragui M; Wagemann O; Balasa M; Kac PR; Barroeta I; Lladó A; Brum WS; Videla L; Gonzalez-Ortiz F; Benejam B; Arranz Martínez JJ; Karikari TK; Nübling G; Bejanin A; Benedet AL; Blesa R; Lleó A; Blennow K; Sánchez-Valle R; Zetterberg H; Fortea J
EBioMedicine; 2023 Apr; 90():104547. PubMed ID: 37002988
[TBL] [Abstract][Full Text] [Related]
26. Sleep and APOE-ε4 have a synergistic effect on plasma biomarkers and longitudinal cognitive decline in older adults.
Yu X; Zhou X; He Z; He B; Wan K; Wei M; Guo T; Han Y
CNS Neurosci Ther; 2024 Feb; 30(2):e14558. PubMed ID: 38421124
[TBL] [Abstract][Full Text] [Related]
27. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
28. Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
Ramanan VK; Graff-Radford J; Syrjanen J; Shir D; Algeciras-Schimnich A; Lucas J; Martens YA; Carrasquillo MM; Day GS; Ertekin-Taner N; Lachner C; Willis FB; Knopman DS; Jack CR; Petersen RC; Vemuri P; Graff-Radford N; Mielke MM
Neurology; 2023 Oct; 101(14):e1402-e1411. PubMed ID: 37580163
[TBL] [Abstract][Full Text] [Related]
29. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM
Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378
[TBL] [Abstract][Full Text] [Related]
30. Combination of plasma amyloid beta
Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
[TBL] [Abstract][Full Text] [Related]
31. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years.
Stocker H; Beyer L; Perna L; Rujescu D; Holleczek B; Beyreuther K; Stockmann J; Schöttker B; Gerwert K; Brenner H
Alzheimers Dement; 2023 Jan; 19(1):25-35. PubMed ID: 35234335
[TBL] [Abstract][Full Text] [Related]
32. Association of
Shang L; Dong L; Huang X; Wang T; Mao C; Li J; Wang J; Liu C; Gao J
Front Aging Neurosci; 2023; 15():1119070. PubMed ID: 37065463
[TBL] [Abstract][Full Text] [Related]
33. Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population.
Ohara T; Tatebe H; Hata J; Honda T; Shibata M; Matsuura S; Mikami T; Maeda T; Ono K; Mimura M; Nakashima K; Iga JI; Takebayashi M; Tokuda T; Ninomiya T;
Psychiatry Clin Neurosci; 2024 Jun; 78(6):362-371. PubMed ID: 38606661
[TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
35. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study.
Verberk IMW; Laarhuis MB; van den Bosch KA; Ebenau JL; van Leeuwenstijn M; Prins ND; Scheltens P; Teunissen CE; van der Flier WM
Lancet Healthy Longev; 2021 Feb; 2(2):e87-e95. PubMed ID: 36098162
[TBL] [Abstract][Full Text] [Related]
36. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC
Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967
[TBL] [Abstract][Full Text] [Related]
37. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
38. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
[TBL] [Abstract][Full Text] [Related]
39. The impact of exercise on blood-based biomarkers of Alzheimer's disease in cognitively unimpaired older adults.
Sewell KR; Rainey-Smith SR; Pedrini S; Peiffer JJ; Sohrabi HR; Taddei K; Markovic SJ; Martins RN; Brown BM
Geroscience; 2024 Mar; ():. PubMed ID: 38488949
[TBL] [Abstract][Full Text] [Related]
40. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.
Jack CR; Wiste HJ; Algeciras-Schimnich A; Weigand SD; Figdore DJ; Lowe VJ; Vemuri P; Graff-Radford J; Ramanan VK; Knopman DS; Mielke MM; Machulda MM; Fields J; Schwarz CG; Cogswell PM; Senjem ML; Therneau TM; Petersen RC
Alzheimers Dement; 2024 Mar; 20(3):2143-2154. PubMed ID: 38265198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]